Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
Senior FDA leaders are anticipating that the agency’s already lagging rate of routine food and drug inspections will ...
Havas Lynx New York also hired Megan Skelly as chief creative officer. Skelly’s 30-year career has included spells at agencies including Edelman, R/GA, 360i and Dentsu.
As Nxera Pharma proceeds into the “next era” implied by its name—following a rebrand from Sosei Group last year—the Japanese ...
With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...
“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...
In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...
Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. | Amid a dramatic reshaping of the federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback